Professor Erika Lietzan has published a new article, Early Access to Unapproved Medicines in the United States and France, 19 Yale J. Health Pol’y L. & Ethics (2020). She, along with co-author Isabelle Moine-Dupuis, wrote about the new U.S. law on early access to experimental medicine. Lietzan and Moine-Dupuis explore the historical, legal, and cultural differences in the early access systems…
Category: Prof. Erika Lietzan ⋅ Page 2
Professor Lietzan speaks at The Federalist Society’s COVID-19 & the Law Conference
Professor Erika Lietzan spoke at The Federalist Society’s COVID-19 & the Law Conference, contributing to the panel Regulation or “Don’t Let a Good Crisis Go to Waste.” She focused on decisions by regulators to de-regulate during the crisis — decisions to exercise enforcement discretion, to waive paperwork requirements, and to remove otherwise applicable restrictions — including decisions made by FDA…
Professor Lietzan lectures at World Intellectual Property Organization summer program
On June 12, Professor Erika Lietzan delivered a lecture on intellectual property in the life sciences sector as part of the WIPO-CPIP Summer School. This exclusive two-week summer course provides a deep dive into IP law and policy for students, professionals, and government officials from around the world. Professor Lietzan explained what makes intellectual property law and policy different in…
Professor Lietzan speaks to Akron law students about perils of patent reform
At a recent event at the University of Akron School of Law, Professor Erika Lietzan spoke about what she called the “assault on drug patents,” including patent reform activity in Congress as well as proposals to prevent drug companies from patenting any changes or improvements to their drugs after approval (so called “one and done” proposals). She explained that medical…
Professor Lietzan’s Research Analyzes Patent Terms for New Medicine
A recent article in Bloomberg Law, U.S. Patent System Crimps Drug Innovation for Toughest Diseases, looks at the research of Professor Erika Lietzan and Kristina M.L. Acri about how the development of new drugs is affected by the U.S. patent system. Their research will be published in a forthcoming article. Their empirical research looked at 642 approved drugs to determine…
Professor Lietzan Named a “Best Lawyer in America”
Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the sixth year in a row for FDA Law and the twelfth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…
Professor Lietzan Collaborates on Compassionate Use Research in France and the U.S.
Professor Erika Lietzan is spending six weeks in France at the invitation of the Centre de Recherche sur le Droit International des Marchés et des Investissements (CREDIMI) at Université de Bourgogne. At the end of November, she attended a colloquium at the French Supreme Court concerning the rights of children with anonymous biological parents (due to sperm or egg donation) to learn the identities…
Pan American Journal of Public Health Publishes Letter from Professor Lietzan
The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for three pathways to market for biologics, and the earlier article, written by the country’s Minister of Health and Social Protection and his colleagues,…
Professor Lietzan testifies before the U.S. House of Representatives Judiciary Committee
Professor Erika Lietzan testified before the House of Representatives Judiciary Committee on July 27, 2017 in a hearing addressing Antitrust Concerns and the FDA Approval Process. Testimony to House of Representatives Judiciary Committee –…